Raltegravir Pharmacokinetics and Safety in Neonates

Trial Profile

Raltegravir Pharmacokinetics and Safety in Neonates

Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms IMPAACT-P1097
  • Most Recent Events

    • 04 Oct 2017 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2018.
    • 26 Aug 2014 Interim results (n=22) published in the JAIDS.
    • 24 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top